Evidence map›Paper›PMID 35053544›Full record

ArticleCancers2022

Whole-Body MRI Surveillance-Baseline Findings in the Swedish Multicentre Hereditary

Meis Omran, Emma Tham, Yvonne Brandberg, Håkan Ahlström, Claudia Lundgren, Ylva Paulsson-Karlsson, Ekaterina Kuchinskaya, Gustav Silander, Anna Rosén, Fredrik Persson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Meis OmranDepartment of Oncology-Pathology, Karolinska Institute, SE-171 77 Stockholm, Sweden.ORCID 0000-0001-5485-6566
Emma ThamDepartment of Molecular Medicine and Surgery, Karolinska Institute, SE-171 77 Stockholm, Sweden.ORCID 0000-0001-6079-164X
Yvonne BrandbergDepartment of Oncology-Pathology, Karolinska Institute, SE-171 77 Stockholm, Sweden.
Håkan AhlströmDepartment of Surgical Sciences, Section of Radiology, Uppsala University, SE-751 85 Uppsala, Sweden.
Claudia LundgrenDepartment of Immunology, Genetics and Pathology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Ylva Paulsson-KarlssonDepartment of Immunology, Genetics and Pathology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Ekaterina KuchinskayaDepartment of Clinical Genetics, Linköping University Hospital, SE-581 91 Linköping, Sweden.
Gustav SilanderDepartment of Radiation Sciences, Umeå University, SE-901 87 Umeå, Sweden.
Anna RosénDepartment of Radiation Sciences, Umeå University, SE-901 87 Umeå, Sweden.ORCID 0000-0003-2441-2395
Fredrik PerssonDepartment of Clinical Genetics and Genomics, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden.
Henrik LeonhardtDepartment of Radiology, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden.
Marie Stenmark-AskmalmDivision of Clinical Genetics, Department of Laboratory Medicine, Office for Medical Services, Skåne University Hospital, SE-228 85 Lund, Sweden.ORCID 0000-0003-4977-4464
Johanna BergDepartment of Translational Medicine, Radiology Diagnostics, Lund University, SE-205 02 Malmö, Sweden.
Danielle van WestenCentre for Medical and Imaging and Function, SE-221 85 Lund, Sweden.
Svetlana Bajalica-LagercrantzDepartment of Oncology-Pathology, Karolinska Institute, SE-171 77 Stockholm, Sweden.ORCID 0000-0002-7175-7102
Lennart BlomqvistDepartment of Molecular Medicine and Surgery, Karolinska Institute, SE-171 77 Stockholm, Sweden.
the Swedish Clinical TP53 Study Group (SweClinTP53)

Funding

Stockholm County CouncilThe Breast Cancer Theme Center (BRECT) at Karolinska Institutet and Karolinska University HospitalThe Cancer Society in StockholmThe King Gustaf V Jubilee FundThe Rare Disease Research FoundationThe Swedish Cancer FundThe Swedish Childhood Cancer Fund
6 · The paper itself

Abstract

A surveillance strategy of the heritable

Indexed as

cancercancer preventionclinically actionable TP53 variantgermline TP53hereditary breast cancerhereditary cancer syndromehTP53rc syndromeLi–FraumeniMRI screeningsurveillance programwhole-body MRI

Identifiers

PMID35053544
PMCPMC8773910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.